Budget Impact Analysis of Sacubitril/Valsartan Introduction For Heart Failure Treatment From The French Hospital Perspective

The study objective was to estimate the budget impact related to sacubitril/valsartan introduction in treatment strategy for patients with symptomatic chronic heart failure (HF) and reduced ejection fraction. The ESC 2012 HF guidelines recommend treatment with an ACE inhibitor or angiotensin II receptor blocker. Sacubitril/valsartan demonstrated a significant risk reduction of cardiovascular deaths by 20% and hospitalizations for HF by 21% versus enalapril, an ACE inhibitor.

Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: C Cariou, E Duteil, M Sion, N Mahieu, J Duco, A Achouba Source Type: research